Lymphedema, swelling caused by a blockage in the lymphatic system, can occur as a result of surgical or radiation therapy associated with breast cancer treatment. Since some research has shown that exercise after breast cancer treatment has been associated with developing lymphedema, clinicians often advise patients to avoid exercising. But is this truly necessary?
This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
In an expected move, the FDA has withdrawn its accelerated approval of Avastin (bevacizumab) for the treatment of breast cancer. Specifically, bevacizumab is no longer indicated for use in combination with paclitaxel for patients with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
Women with breast cancer have a new ally in their fight, as researchers now believe zoledronic acid will help prevent bone loss associated with adjuvant aromatase inhibitor therapy. The latest results from the Z-FAST trial were published in Cancer by Dr Adam M. Brufsky, professor of medicine at the University of Pittsburgh School of Medicine and associate director of clinical investigation for the University of Pittsburgh Cancer Institute, and colleagues.
Reassuring news for clinicians treating pregnant patients with cancer: chemotherapy does not appear to cause developmental problems in offspring. Dr Frederic Amant, assistant professor, staff gynecologic oncologist, and head of the scientific section of gynecologic oncology at Katholieke Universiteit in Leuven, Belgium, presented these findings at the 2011 European Multidisciplinary Cancer Congress.
Following two days of hearings, the US Food and Drug Administration has declared that silicone breast implants are safe for use and will remain available. However, the FDA will encourage manufacturers to conduct post-approval studies.
Are younger women with breast cancer more likely to develop another primary cancer later in life as compared to their older counterparts? According to some experts, younger women may have more unfavorable tumor characteristics. Others hypothesize this increase is observed because younger women can be observed for longer periods. To better understand this phenomenon, Dr Lene Mellemkjaer, senior researcher at the Institute of Cancer Epidemiology of the Danish Cancer Society in Copenhagen, Denmark, and colleagues conducted a study of 304,703 women who received a diagnosis of breast cancer between 1943 and 2006 according to registries in Denmark, Norway, and Finland.
A new recommendation by The American College of Obstetricians and Gynecologists urges physicians to offer mammography screening annually to women beginning at age 40 years. The College previously recommended that women aged 40 years receive mammograms every 1 to 2 years and women aged 50 years have mammograms annually.
Advances in the treatment for breast cancer have allowed for better outcomes and decreased mortality rates. Tamoxifen, the oldest and most frequently prescribed selective estrogen receptor modulator approved by the US Food and Drug Administration, has shown great efficacy, and studies of tamoxifen treatment lasting 5 years now have follow-up efficacy data that go past one decade. To better understand the evidence, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) conducted a meta-analysis of 20 trials to ascertain the protective effects of tamoxifen in reducing recurrence and death ratios.
Mammography screening should be offered annually to women beginning at age 40 years, according to a new recommendation by The American College of Obstetricians and Gynecologists (The College).1 This change was brought about by the high incidence of breast cancer in the United States. Early detection of breast cancer has the potential to reduce the number of breast cancer–related deaths. The College previously recommended that women aged 40 years receive mammograms every 1 to 2 years and women aged 50 years have mammograms annually.